With CAR-T marketing looming, early study highlights potential of TCR engineering – Endpoints News
Endpoints News |
With CAR–T marketing looming, early study highlights potential of TCR engineering
Endpoints News This week, a research team led by the NIH's Steven Rosenberg — whose work has been used as a basis of Kite Pharma's pioneering CAR-T — rolled out early proof-of-concept data from a small human study using a CD4+ T cell adapted with a T cell receptor … |
